Pre-treatment PD-L1+ CTCs are usually associated with a bad prognosis in patients treated with PD-1 inhibitors in NSCLC, such as nivolumab (Guibert et al., 2018). This evidence concerns the gene CD274 and non-small cell lung carcinoma.